In a recently published commentary about the optimal type of multi-modal hormone therapy for Gleason grade 4 and 5 prostate cancer the author addressed the discordance between results of several randomized trials evaluating survival benefit of continuous androgen deprivation therapy in men with high-risk disease. The study found that after combining data from multiple trials, [...]
Clinical trials have shown that there is an overall survival and radiographic progression-free survival benefit derived from abiraterone acetate (Zytiga) in the treatment of men with metastatic castration resistant prostate cancer (mCRPC). A new retrospective study published online, ahead of print, shows this trend is true regardless of a man's Gleason score at diagnosis, despite [...]
Choline-C11 PET/CT scans can identify the actual sites of recurrence of prostate cancer in men who have a rising PSA after receiving primary therapy. The question worth asking is if this type of scan might be able to be used for prognostic purposes. Knowing this might influence our treatment decisions as well as our basic [...]
